Adaptic® Česká republika - čeština - Adama

adaptic®

adama - rozpustný koncentrát - amonium sulfate + polyacrilamid - smáčedla

ESOPREX OROTAB 10MG Tableta dispergovatelná v ústech Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

esoprex orotab 10mg tableta dispergovatelná v ústech

zentiva, k.s., praha ČeskÁ republika - 16590 escitalopram-oxalÁt - tableta dispergovatelná v ústech - 10mg - escitalopram

Azacitidine Mylan Evropská unie - čeština - EMA (European Medicines Agency)

azacitidine mylan

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastická činidla - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Azacitidine Celgene Evropská unie - čeština - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastická činidla - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.